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Current Research of Extracorporeal Photopheresis and
Future Applications
Chaim Lederer
Abstract
Photopheresis, also known as Extracorporeal Photopheresis (ECP) is making inroads in treatment of previously untreatable diseases. As the medical world has delved deeper into, Although the mechanisms of photopheresis are largely unknown, increasingly detailed studies have proven its efficacy. The lack of side effects has made photopheresis an ideal
option for patients. The treatment is also versatile enough that it can be used as a mono-therapy or as a supplement to
other traditional therapies. The use of photopheresis has been proven successful in the treatment of cutaneous T-cell
lymphoma (CTCL) and graft-versus-host disease (GvHD), and is currently being administered for immune system disorders, bone marrow, or stem cell implantation, liver, heart, or lung transplants (where there is fear of rejection) and any

ous types of blood components such as erythroid cells,
platelets, myeloid cells (such as neutrophils, basophils, eosinophils, monocytes), mast cells, natural killer cells, dendritic cells, natural killer T cells, thymus derived cells (T
cells), and B cells depending on the environment and stimuli (Lensch, 2012). These immune cells arrange host protection by responding to foreign antigens after the cells
mature. However, a proper maintenance of cellular and
molecular balance is crucial for these immune responses
to proceed. Once this delicate balance is askew, normal
immunity is disrupted and diseases with increased susceptibility to infection arises.

Introduction
Research in the field of Extracorporeal Photopheresis (ECP) commenced in 1982. Richard Edelson,
MD, a Professor at Columbia University, had been experimenting with a therapy he invented as an alternative treatment for untreatable cancers. After many years of research, he achieved an astonishing clinical success in the
treatment of two patients with extensive cutaneous T-cell
lymphoma (CTCL). Previously, in the 1970’s, Dr. Edelson
noted that removing circulating cancer cells from patients
with Sezary Syndrome (SS), a form of CTCL, by way of repetitive Leukapheresis, resulted in a temporary improvement in their skin disease. Leukapheresis is a procedure
that removes abnormal white blood cells from the
blood. It is a form of apheresis, which is the process of
removing one particular constant from the blood and returning the rest to circulation. In the 1980’s, Dr. Edelson
collaborated with Therakos, a Johnson and Johnson company, to design a device to accomplish Leukapheresis while
simultaneously exposing a small amount of the patients’
white blood cells to Methoxsalen, a light sensitizing drug,
and ultra violet (UVa) light to activate the medication.

Within the immune system, the Dendritic cells
(DC) are antigen-presenting cells. The DCs, also known as
accessory cells, play an integral role in both inborn immunity and adaptive immunity. The cells link inborn and adaptive immunity by activating B and T-cells through the
presentation of antigens on their cell surfaces (Novak, et
al, 2010). When B-cells are triggered by DCs, an immune
response consisting of secretion of antigen specific antibodies occurs. Simultaneously, DCs activate CD4+ helper
and CD8+ T-cells that define and stimulate T-cell responses
specific to each antigen (Banchereau, Steinman,
Immunity: Background Information
1998). Depending on the nature of the antigen, different
The immune system consists of differentiated CD4+ T-helper (Th) responses such as Th-1, Th-2, Th-17,
hematopoietic cells that are created from bone marrow and T-regulation can occur. Th-cells also secrete cytokines
hematopoietic stem cells (HSC). HSCs separate into vari- that promote cell interactions with additional cells, which
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are then dispatched to the infected site. For example, the
Th-1 response is mediated by CD4+ helper T-cells and
CD8+ T-5 cells that secrete IFN-γ, IL-2, and IL-12 to fight
against viruses. The CD4+ helper cells then “help” to invoke a cytotoxic attack against the virus, mainly through
CD8+ cytotoxic T-cells (Steinman, Hemmi, 2006)
(Kadowaki, 2007) .

foliative dermatitis, and adenopathy (inflammation of the
lymph nodes). Patients with SS do not have a good prognosis; there is an average survival rate of only 3 years
(Scarisbrick, et al, 2001). SS patients have been found to
have a high rate of Staph colonization. Secondary and hospital acquired infections, most often from Staphylococcus
aureus (Staph) sepsis due to an impaired immune system,
breaks in the skin and use of catheters are particularly fatal
in SS patients. The cause of SS is unknown and the diagnosis is very difficult due to its similarities to other skin ailments. It was originally believed that SS was derived from
MF. However, MF and SS can be differentiated since MF
cells are effector memory T-cells and SS cells are central
memory T-cells. With Sèzary cells, they are also found in
both the blood and skin with CD4+ T cells lacking the expression of CD-26 or CD-7. (Campbell, et al, 2010)

Located in the immune system, T-regulatory cells
(T-regs) regulate a wide variety of immune cells such as
CD4+, CD8+, B-cells, natural killer T-cells, and antigen presenting cells (APC) both in vitro (artificial environment)
and in vivo (natural environment). These cells make up 510% of the total agranulocytic cells found in the body’s
blood (Sakaguchi, 2008). They have the distinct ability to
regulate reactions in the immune system, preventing immune diseases such as allergies and autoimmunity. T-regs
have often been recognized as the cause for failure of cancer vaccines. On the other hand, T-regs also have potential
use for patients with irregular immune systems. In autoimmune patients, an increase in T-regs may be an ideal method of treatment since their immune system is compromised and these cells could help regulate it. Similarly, the
removal of T-regulatory cells may assist in increasing a cytotoxic response to tumor antigens.

Graft-versus-Host Disease (GvHD)
Graft-versus-host disease (GvHD) is an immune
system disorder that limits the use of stem cell and bone
marrow transplant therapies. The donor immune cells
used in the transplant recognize host cells as being foreign,
based on human leukocyte antigen (HLA) mismatch. The
donor cells mount an immunological attack, resulting in
damage to organs including the skin, gut, liver, eyes, or
lungs.

Cutaneous T-cell Lymphoma (CTCL)
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin’s peripheral T-cell lymphomas
that mainly affect the skin. Two of the most common
forms of CTCL are Mycosis Fungoides (MF) and Sézary Sydrome (SS). They are distinguished by malfunctioning CD4+
T-cells and impaired immunity. Together they encompass
approximately 70% of all CTCL cases. About 1,500 new
cases of MF/SS are reported yearly, and there are currently
16,000-20,000 individuals living in the United States with
MF/SS (Criscione, Weinstock, 2007). CTCLs are incurable
and thought to arise from uncontrolled reproduction and
accumulation of atypical mature helper, memory clonal Tlymphocytes (Vonderheid, Bernengo, 2003).

There are two types of GVHD, acute GVHD and
chronic GVHD. Symptoms occurring within 100 days posttransplant are described as acute GVHD and any occurrence of symptoms beyond 100 days are characterized as
chronic GVHD. An analysis of acute GVHD showed that
amongst the patients affected 81% had skin involvement,
54% had gastrointestinal involvement, and 50% had liver
involvement (Martin, et al, 1990). Candidates for transplant therapies have a plethora of ailments which can lead
to incrased numbers of antigen presenting cells resulting
from damages produced by a multitude of factors such as
underlying disease and its treatmentvia chemotherapy,
radiation, and infections. In order to prepare the host’s
body for transplantation, the patient has to undergo a proSézary Syndrome (SS)
cedure called total body irradiation. Total body irradiation
Discovered and introduced by Albert Sézary in is used to suppress the immune system, thus preventing
1938, Sézary Syndrome (SS) is a form of leukemia con- the patient’s immune system from destroying implanted
sisting of cells with cerebriform shaped nuclei, itching, ex- cells that are foreign to the body. During this procedure,
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inflammatory cytokines such as IL-1 and tumor necrosis
factors (TNF) are secreted from the patient’s tissues. Cytokines, which can potentially cause damage to
the gastrointestinal tract via endothelial apoptosis, may
increase the severity of GvHD if the microbial products
such as bacteria attack the blood system. Activation of the
immune system or tolerance by the body is controlled by
APC’s that are activated by these secretions (Roncarolo, et
al, 2001).

the latter, with almost no risk of side effects.
In the ECP procedure that was created by the
Therakos company, blood is drawn from the arm or a central catheter, and a very small amount (5x109) of the patients white blood cells (3-5%) are separated and collected
for irradiation or apheresis. The blood is centrifuged to
separate the leukocyte enriched blood portion from the
red blood cells in plasma. The rest of the blood is automatically returned to the bloodstream. The collected white
blood cells are then treated with a medicine called Methoxsalen/Uvadex. The drug is activated when it is exposed
to ultra-violet (UV) light. The medicated white blood cells
are exposed to UVa light, with a strength of 1.5 J/
cm^2. The function of the medication is to covalently bind
and cross-link DNA, leading to apoptosis of treated
cells. These cells are now known as Methoxsalen treated
buffy coat cells. The buffy coat cells are then re-infused
back into the patient . so that they can cause an immune
response. In the body, the spleen and the liver now pick
up the Methoxsalen treated white blood cells. The day
after ECP treatment, the treated cells undergo apoptosis.
Even though the mechanism is not understood, these cells
are phagocytized by antigen presenting cells (APC) that are
causing disorder in the body. It is theorized that the phagocytosis causes a regulation of immune responses by altering the APC function. The APC’s now become immunological tolerant inducing or tolerogenic to the immune system. The phagocytosis causes a decrease in the secretion
of pro-inflammatory cytokines and effector Tcells.
Additionally, it causes an increase in antiinflammatory cytokines such as TGF-beta and IL-10. This
process and reaction causes a boost in the activation and
stimulation of T-regulatory cells which in turn leads to a
healthy regeneration and rebalancing of the T-cells and
other immune cells in the body. Additionally, blood that
has been irradiated halts lymphocytes from causing harm
to patients who have compromised immune systems. ECP
does not cause any known harm to the body, and the
blood does not become radioactive or toxic.

In the cells there is a major histocompatibililty
complex (MHC). The MHC is a set of molecules on the surface of the cells which facilitates the interactions of leukocytes (WBCs). CD4+ and CD8+ T-cells, and cytokines are
the main disease facilitators. In every individual, the MHC
takes on its own unique genetic coding. One of the primary functions of the MHC is the recognition of foreign antigens invading the immune system. Since the MHC is highly
polymorphic, it has the ability to recognize countless types
of antigens. It then binds peptide fragments taken from
the pathogens and displays them on the cell surface for
recognition by the T-cells. The MHC presents the antigens
to the T-cell receptor (TCR), and the T-cells are activated or
deactivated via an interaction between the TCR and the
MHC. In the case of GvHD, everything is awry because the
grafted T-cells fail to recognize the MHC proteins on host
cells. Due to the MHC mismatch, the graft T-cells attack
the host cells thinking they are foreign even though they
are non-antigenic. Thus, the MHC mismatch contributes to
the disrupted normal immunity leading to GVHD.

Extracorporeal Photopheresis (ECP)

Extracorporeal Photopheresis is a pioneering treatment with minimal side effects, which improves the quality
of life, and has increased the survival rates for persons
with select incurable diseases. Based on clinical trials, the
procedure was approved by the FDA for treatment of
erythrodermic Leukemic-CTCL (L-CTCL) (Edelson, et al,
1987). At the time, response rates between 54% and 66%
had been reported in L-CTCL patients with about 10% complete responders (Jiang, et al, 1999) (Crovetti, et al,
Since there was some understanding as to how
2000). This opened up a new world of possibilities in the
ECP was able to achieve these positive results, it brought
treatment of cancers. Most cancer treatments come with a
about the possibility of expanding its usage for other selarge amount of side effects along with the possibility of a
vere diseases. These diseases include: multiple sclerosis
cure. This treatment had the potential of accomplishing
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(MS), systemic sclerosis, Crohn’s disease, rheumatoid arthritis, type-1-diabetes, and autoimmune diseases such as
lupus. Trials have also begun in cases of whole transplanted organ rejection. In CTCL patients, ECP has shown the
successful destruction of malignant T-cells via apoptosis
and the differentiation of monocytes into effective antigen
presenting dendritic cells. These two outcomes concurrently lead to a decrease of the tumor load and initiation
of antitumoral immune response. (Garban, et al, 2012).

Studies
Studies have shown the efficacy of ECP treatment
in patients with early-stage mycosis fungoides (MF). The
studies were conducted with ECP as a mono-therapy and
as a supplement to the traditional cancer therapies. The
patients underwent treatment of ECP for two days every
four weeks over a time span of six months. Those that had
a partial response continued the treatment of ECP for the
full six months and those without an initial response added
oral bexarotene and/or interferon α. These studies produced astonishingly positive results.
Participants included nineteen patients with earlystage MF (7 men, 12 women; 16 white, 3 African American) with an average age of 63.5 years (range, 46-85
years). 42% of the participants responded to the ECP by
itself with an average amount of 12 ECP sessions over 12
months (8/19; including 7 partial response, 1 complete
response). Seven of the patients with stabilized MF at 3
months received additional bexarotene treatment (3/5; 1
complete response) or were administered bexarotene
plus interferon α (1/2), and 57% (4/7) responded to the
updated treatment. Side effects were limited to those expected with standard chemotherapy treatment. The
effects included nausea, vomiting, and diarrhea.

ment. These patients received ECP on 2 consecutive days
every one to two weeks, until there was a noticeable response and continued every two to four weeks until it
reached a maximum response. The next stage conducted
was a study of the relationship of mortality and survival.
The 4-year survival rate for those in whom acute GVHD
had a complete response was 59% (Kumar, 2011).
When ECP was first introduced into the medical
world, it was only proven to work on CTCL and GvHD. Due
to the success, the research community continued looking
to see which other ailments the treatment could be applied to. This has become a worldwide concerted effort in
attempt to make headway in previously incurable diseases
and clinical trials have begun on the effect of ECP on many
different unrelated or atypical diseases..
Another case where the curative effects of ECP
can be observed is through studies involving patients
afflicted with Crohn’s disease, who are incapable of responding to alternative treatments such as immunesuppressants and/or anti-TNF therapies. After twelve sequential weeks of treatment, the success of the individual’s results were evaluated based on the patient’s decrease
in their Crohn's Disease Activity Index (CDAI) of less than
or equal to 100 points, or the remission which can be characterized by an index of less than 150 points. From the 28
patients that participated in the study, half successfully
responded to the treatment with 13 subjects reacting at
week 6, and 7 of them obtaining remission after the 12week interval. From the 12 patients who chose to advance
with a 12-week extension study, 9 continued to effectively
respond to the treatment. Through their study, clinicians
were capable in discerning ECP as a productive means in
which patients with Crohn’s disease were able to attain
desirable results (Abreu et. al.. 2009).

The studies proved that ECP is effective for paConclusion
tients with early-stage MF alone or in combination with
Beginning with the initial successes in the 1980’s,
drugs and included improved quality of life. It has shown a
response of as high as 42% with ECP treatment alone extracorporeal photophersis has been a medical breakthrough in a field where there rarely is a cure found
(Talpur, et al, 2011)
with limited or no side effects. The difficulty of underAnother study was on the efficacy of ECP on sterstanding how it achieves its results has not been a deteroid-dependent acute GVHD. A complete resolution was
rent to further expansion of its usage. Today, ECP is at the
attained in 82% of patients with skin involvement, 61%
forefront of clinical trials bringing hope to many with limwith liver involvement, and 61% with gut involve77
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ited options or where the cure is sometimes just as deadly
as the disease, as is the case in chemotherapy and radiation treatments. With its versatility, ECP becomes an additional option even for patients already using other therapies. Trials have produced extremely promising results for
diseases with little or no hope. To date, ECP has only been
approved for treatment in CTCL and GvHD, but current
trials are expanding its usage. ECP has promising potential
to be the cure of the future pertaining to immune system
related diseases.
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